Top Glove Bhd AI Stock Analysis
Want to see TGLVY full AI Analyst Report?
Top Glove Bhd (TGLVY) AI Stock Analysis
Top Glove Bhd
(Other OTC:TGLVY)
The score is driven primarily by improving financial performance (return to profitability, positive and growing free cash flow, and low leverage), tempered by a history of pronounced cyclicality. Technically, the uptrend is supported by moving averages and positive MACD, but overbought RSI/Stoch readings add near-term risk. Valuation is mixed: a mid-range P/E alongside an unusually high dividend yield, but with uncertainty given recent earnings volatility.
Top Glove Bhd (TGLVY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.87B
- Dividend Yield
- 0.50%
- Average Volume (3M)
- 1,711
- Price to Earnings (P/E)
- 24.2
- Beta (1Y)
- -0.24
- Revenue Growth
- 30.02%
- EPS Growth
- 203.20%
- Country
- US
- Employees
- 10,600
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Top Glove Bhd Business Overview & Revenue Model
Company Description
Founded in Shah Alam, Malaysia, in 1991, Top Glove Corporation Bhd. primarily operates as an investment holding company, offering comprehensive management services. The company is a major manufacturer, specializing in a wide array of gloves, includin...
How the Company Makes Money
Top Glove primarily makes money by manufacturing disposable gloves and selling them to customers in domestic and international markets. Revenue is generated from (1) sales of glove products across different material types (e.g., natural rubber latex...
Top Glove Bhd Financial Statement Overview
Summary
Recovery is evident with TTM revenue up 9.4%, a return to solid profitability (~7.3% net margin; ~17.2% EBITDA margin), and positive/free cash flow (FCF up ~16%). Offsetting this, earnings and cash flow have been highly cyclical (pandemic-era peak profits followed by losses in 2023–2024), and cash conversion is only moderate (FCF ~0.79x net income). Low leverage (debt-to-equity ~0.17) supports resilience.
Income Statement
62PositiveBalance Sheet
78PositiveCash Flow
66Positive| Breakdown | TTM | Aug 2026 | Aug 2025 | Aug 2024 | Aug 2023 | Aug 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.24B | 4.05B | 3.49B | 2.51B | 2.26B | 5.57B |
| Gross Profit | 2.22B | 389.07M | 89.01M | 265.32M | 64.32M | 953.38M |
| EBITDA | 715.55M | 696.52M | 455.66M | 266.09M | -544.66M | 711.00M |
| Net Income | 307.50M | 294.90M | 132.18M | -18.27M | -878.61M | 275.73M |
Balance Sheet | ||||||
| Total Assets | 6.69B | 6.69B | 6.27B | 6.96B | 7.06B | 8.12B |
| Cash, Cash Equivalents and Short-Term Investments | 978.20M | 978.20M | 560.67M | 933.23M | 942.82M | 946.75M |
| Total Debt | 852.95M | 852.95M | 849.86M | 422.09M | 581.85M | 417.07M |
| Total Liabilities | 1.69B | 1.69B | 1.49B | 1.12B | 1.14B | 1.32B |
| Stockholders Equity | 4.97B | 4.97B | 4.76B | 5.81B | 5.89B | 6.75B |
Cash Flow | ||||||
| Free Cash Flow | 324.53M | 415.97M | 156.31M | -122.54M | -244.10M | -774.72M |
| Operating Cash Flow | 423.76M | 529.12M | 300.16M | 20.70M | 121.04M | 178.81M |
| Investing Cash Flow | -324.78M | -413.57M | 450.90M | 247.46M | -383.26M | 132.42M |
| Financing Cash Flow | -26.20M | -30.38M | -803.47M | -181.66M | 94.75M | -740.35M |
Top Glove Bhd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGLVY, the sentiment is Positive. The current price of 0.93 is above the 20-day moving average (MA) of 0.88, above the 50-day MA of 0.79, and above the 200-day MA of 0.68, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 58.76 is Neutral, neither overbought nor oversold. The STOCH value of 36.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TGLVY.
Top Glove Bhd Peers Comparison
Overall Rating
TGLVY66Neutral
MDLN65Neutral
ICUI64Neutral
BDX63Neutral
BAX58Neutral
SOLV50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 66Neutral | $1.82B | 24.22 | 6.39% | 0.50% | 30.02% | 203.20% | |
| 65Neutral | $49.57B | 56.52 | 4.97% | ― | 11.85% | -57.19% | |
| 64Neutral | $4.42B | 74.27 | 2.81% | ― | -5.82% | ― | |
| 63Neutral | $58.68B | 52.05 | 4.64% | 1.85% | -7.40% | -28.89% | |
| 58Neutral | $13.33B | -18.63 | -11.62% | 0.16% | 5.33% | -164.67% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $14.61B | 97.47 | 3.18% | ― | -3.09% | -89.72% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TGLVY | Top Glove Corporation | 0.93 | 0.38 | 67.99% | |
| BAX | Baxter International Inc | 25.76 | 8.11 | 45.91% | |
| BDX | Becton, Dickinson and Co | 215.42 | 68.81 | 46.94% | |
| ICUI | ICU Medical | 176.91 | 44.34 | 33.45% | |
| SOLV | Solventum Corporation | 86.06 | 8.75 | 11.32% | |
| MDLN | Medline, Inc. Class A | 37.68 | -3.32 | -8.10% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 08, 2026
